Immuno-Oncology Market By Therapy, (Immune Checkpoint Inhibitors, Monoclonal Antibodies (mAbs), Cell & Gene Therapies, Cancer Vaccines, Oncolytic Virus Therapy, Combination Therapies), By Indication (Solid Tumours, Hematologic Malignancies), By Stage/ Line of Therapy (First-line (frontline), Second-line, Third-line/later lines, Adjuvant (post-surgery), Neoadjuvant (pre-surgery)), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Published date: Oct 2025
Report ID: 143626
Number of Pages: 250
Format:

Fact Checked

Cite this Research

Table of Contents
- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Market Snapshot
  - 1.3. Market Overview
  - 1.4. Segment Overview
  - 1.5. Regional Overview
  - 1.6. Competitive Landscape
  - 1.7. Taxonomy
  - 1.8. Industry Voices
- 2. Global Market Overview
  - 2.1. Global Market Insights and Industry Overview
  - 2.2. Market Dynamics
    
    2.2.1. Drivers
    
    2.2.2. Restraints
    
    2.2.3. Opportunities
    
    2.2.4. Key Immuno-Oncology Market Trends
  - 2.3. Indication Landscape
  - 2.4. Regulatory Framework
  - 2.5. Sustainability and ESG (Environmental, Social, Governance)
  - 2.6. Opportunity Map Analysis
  - 2.7. Opportunity Orbits
  - 2.8. PESTLE Analysis
  - 2.9. PORTER’S Five Force Analysis
  - 2.10. Drivers & Restraints Impact Analysis
  - 2.11. Value Chain Analysis
    
    2.11.1. List of Raw Materials Suppliers
    
    2.11.2. List of Immuno-Oncology Manufacturers
    
    2.11.3. List of Dealer/Distributors
  - 2.12. Regional Market Share and BPS Analysis
  - 2.13. Impact of Macro-economic Factors/Geopolitical Factors
- 3. Global Immuno-Oncology Market Analysis and Forecast, By Segment, 2020-2034
  - 3.1. Key Findings
  - 3.2. Global Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 3.3. Global Immuno-Oncology Market Attractiveness Analysis, By Therapy
    
    3.3.1. Immune Checkpoint Inhibitors
    
    3.3.1.1. Insights
    
    3.3.1.2. Key Takeaways
    
    3.3.1.2.1. PD-1 inhibitors
    
    3.3.1.2.1.1. Nivolumab
    
    3.3.1.2.1.2. Pembrolizumab
    
    3.3.1.2.1.3. Cemiplimab
    
    3.3.1.2.1.4. Dostarlimab
    
    3.3.1.2.2. PD-L1 inhibitors
    
    3.3.1.2.2.1. Atezolizumab
    
    3.3.1.2.2.2. Durvalumab
    
    3.3.1.2.2.3. Avelumab
    
    3.3.1.2.3. CTLA-4 inhibitors
    
    3.3.1.2.3.1. Ipilimumab
    
    3.3.1.2.3.2. Tremelimumab
    
    3.3.1.2.4. LAG-3 inhibitors
    
    3.3.1.2.4.1. Relatlimab
    
    3.3.1.2.4.2. Favezelimab
    
    3.3.1.2.5. TIGIT inhibitors
    
    3.3.1.2.5.1. Tiragolumab
    
    3.3.1.2.5.2. vibostolimab
    
    3.3.1.2.5.3. domvanalimab
    
    3.3.1.2.6. Others
    
    3.3.2. Monoclonal Antibodies (mAbs)
    
    3.3.2.1. Insights
    
    3.3.2.2. Key Takeaways
    
    3.3.2.2.1. Naked mAbs
    
    3.3.2.2.2. Antibody–Drug Conjugates (ADCs)
    
    3.3.2.2.3. Bispecific / Multispecific antibodies
    
    3.3.3. Cell & Gene Therapies
    
    3.3.3.1. Insights
    
    3.3.3.2. Key Takeaways
    
    3.3.3.2.1. CAR-T cell therapy
    
    3.3.3.2.2. CAR-NK / TCR-T / TIL
    
    3.3.3.2.3. Gene-edited immune cells
    
    3.3.4. Cancer Vaccines
    
    3.3.4.1. Insights
    
    3.3.4.2. Key Takeaways
    
    3.3.5. Oncolytic Virus Therapy
    
    3.3.5.1. Insights
    
    3.3.5.2. Key Takeaways
    
    3.3.6. Combination Therapies
    
    3.3.6.1. Insights
    
    3.3.6.2. Key Takeaways
  - 3.4. Global Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 3.5. Global Immuno-Oncology Market Attractiveness Analysis, By Indication
    
    3.5.1. Solid Tumours
    
    3.5.1.1. Insights
    
    3.5.1.2. Key Takeaways
    
    3.5.1.2.1. Lung cancer
    
    3.5.1.2.1.1. NSCLC
    
    3.5.1.2.1.2. SCLC
    
    3.5.1.2.2. Melanoma
    
    3.5.1.2.3. Head & neck cancers
    
    3.5.1.2.4. Bladder/urothelial cancer
    
    3.5.1.2.5. Renal cell carcinoma (RCC)
    
    3.5.1.2.6. Gastric / gastroesophageal cancers
    
    3.5.1.2.7. Colorectal cancer (MSI-H vs MSS)
    
    3.5.1.2.8. Hepatocellular carcinoma (HCC)
    
    3.5.1.2.9. Breast cancer (TNBC, HER2+, etc.)
    
    3.5.1.2.10. Ovarian / cervical / endometrial cancers
    
    3.5.1.2.11. Prostate cancer
    
    3.5.1.2.12. Pancreatic cancer
    
    3.5.2. Hematologic Malignancies
    
    3.5.2.1. Insights
    
    3.5.2.2. Key Takeaways
    
    3.5.2.2.1. Hodgkin lymphoma (classical, nodular lymphocyte-predominant)
    
    3.5.2.2.2. Non-Hodgkin lymphoma (DLBCL, FL, MCL, etc.)
    
    3.5.2.2.3. Leukemias (ALL, AML, CLL)
    
    3.5.2.2.4. Multiple myeloma
    
    3.5.2.2.5. Myelodysplastic syndromes
  - 3.6. Global Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 3.7. Global Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
    
    3.7.1. First-line (frontline)
    
    3.7.1.1. Insights
    
    3.7.1.2. Key Takeaways
    
    3.7.2. Second-line
    
    3.7.2.1. Insights
    
    3.7.2.2. Key Takeaways
    
    3.7.3. Third-line / later lines
    
    3.7.3.1. Insights
    
    3.7.3.2. Key Takeaways
    
    3.7.4. Adjuvant (post-surgery)
    
    3.7.4.1. Insights
    
    3.7.4.2. Key Takeaways
    
    3.7.5. Neoadjuvant (pre-surgery)
    
    3.7.5.1. Insights
    
    3.7.5.2. Key Takeaways
  - 3.8. Global Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 3.9. Global Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
    
    3.9.1. Hospital pharmacies
    
    3.9.1.1. Insights
    
    3.9.1.2. Key Takeaways
    
    3.9.2. Retail pharmacies
    
    3.9.2.1. Insights
    
    3.9.2.2. Key Takeaways
    
    3.9.3. Online pharmacies
    
    3.9.3.1. Insights
    
    3.9.3.2. Key Takeaways
- 4. Global Immuno-Oncology Market Analysis and Forecast, By Region, 2020-2034
  - 4.1. Key Findings
  - 4.2. Global Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    
    4.2.1. North America
    
    4.2.1.1. Regional Insights
    
    4.2.2. Europe
    
    4.2.2.1. Regional Insights
    
    4.2.3. Asia Pacific
    
    4.2.3.1. Regional Insights
    
    4.2.4. Latin America
    
    4.2.4.1. Regional Insights
    
    4.2.5. Middle East & Africa
    
    4.2.5.1. Regional Insights
  - 4.3. Global Immuno-Oncology Market Attractiveness Analysis, By Region
- 5. North America Immuno-Oncology Market Analysis and Forecast, 2020-2034
  - 5.1. Key Findings
  - 5.2. North America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 5.3. North America Immuno-Oncology Market Attractiveness Analysis, By Therapy
  - 5.4. North America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 5.5. North America Immuno-Oncology Market Attractiveness Analysis, By Indication
  - 5.6. North America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 5.7. North America Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
  - 5.8. North America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 5.9. North America Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
  - 5.10. North America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 5.11. North America Immuno-Oncology Market Attractiveness Analysis, By Country
    
    5.11.1. The US
    
    5.11.2. Canada
- 6. Europe Immuno-Oncology Market Analysis and Forecast, 2020-2034
  - 6.1. Key Findings
  - 6.2. Europe Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 6.3. Europe Immuno-Oncology Market Attractiveness Analysis, By Therapy
  - 6.4. Europe Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 6.5. Europe Immuno-Oncology Market Attractiveness Analysis, By Indication
  - 6.6. Europe Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 6.7. Europe Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
  - 6.8. Europe Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 6.9. Europe Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
  - 6.10. Europe Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 6.11. Europe Immuno-Oncology Market Attractiveness Analysis, By Country
    
    6.11.1. Germany
    
    6.11.2. The UK
    
    6.11.3. France
    
    6.11.4. Spain
    
    6.11.5. Italy
    
    6.11.6. Russia
    
    6.11.7. Netherland
    
    6.11.8. Rest of Europe
- 7. Asia Pacific Immuno-Oncology Market Analysis and Forecast, 2020-2034
  - 7.1. Key Findings
  - 7.2. Asia Pacific Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 7.3. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Therapy
  - 7.4. Asia Pacific Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 7.5. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Indication
  - 7.6. Asia Pacific Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 7.7. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
  - 7.8. Asia Pacific Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 7.9. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
  - 7.10. Asia Pacific Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 7.11. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Country
    
    7.11.1. China
    
    7.11.2. Japan
    
    7.11.3. South Korea
    
    7.11.4. India
    
    7.11.5. Australia
    
    7.11.6. New Zealand
    
    7.11.7. Singapore
    
    7.11.8. Thailand
    
    7.11.9. Vietnam
    
    7.11.10. Rest of Asia Pacific
- 8. Latin America Immuno-Oncology Market Analysis and Forecast, 2020-2034
  - 8.1. Key Findings
  - 8.2. Latin America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 8.3. Latin America Immuno-Oncology Market Attractiveness Analysis, By Therapy
  - 8.4. Latin America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 8.5. Latin America Immuno-Oncology Market Attractiveness Analysis, By Indication
  - 8.6. Latin America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 8.7. Latin America Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
  - 8.8. Latin America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 8.9. Latin America Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
  - 8.10. Latin America Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 8.11. Latin America Immuno-Oncology Market Attractiveness Analysis, By Country
    
    8.11.1. Brazil
    
    8.11.2. Mexico
    
    8.11.3. Rest of Latin America
- 9. Middle East & Africa Immuno-Oncology Market Analysis and Forecast, 2020-2034
  - 9.1. Key Findings
  - 9.2. Middle East & Africa Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapy, 2020-2034
  - 9.3. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Therapy
  - 9.4. Middle East & Africa Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Indication, 2020-2034
  - 9.5. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Indication
  - 9.6. Middle East & Africa Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Stage / Line of Therapy, 2020-2034
  - 9.7. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
  - 9.8. Middle East & Africa Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 9.9. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
  - 9.10. Middle East & Africa Immuno-Oncology Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 9.11. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Country
    
    9.11.1. South Africa
    
    9.11.2. Saudi Arabia
    
    9.11.3. UAE
    
    9.11.4. Rest of Middle East & Africa
- 10. Competitive Landscape & Company Profiles
  - 10.1. Market Competition Scenario Analysis, By Company
    
    10.1.1. Key Takeaways
  - 10.2. Overview of Major Market Players
  - 10.3. Competitor Landscape
  - 10.4. Strategic Mapping
  - 10.5. Company Life Cycle Analysis
  - 10.6. Company Market Share Analysis
  - 10.7. Company Profiles
    
    10.7.1. Merck & Co.
    
    10.7.1.1. Company Details
    
    10.7.1.2. Business Overview
    
    10.7.1.3. Product Portfolio
    
    10.7.1.4. Financial Insights
    
    10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.1.6. SWOT Analysis
    
    10.7.1.7. Geographic Footprint
    
    10.7.2. Bristol-Myers Squibb (BMS)
    
    10.7.2.1. Company Details
    
    10.7.2.2. Business Overview
    
    10.7.2.3. Product Portfolio
    
    10.7.2.4. Financial Insights
    
    10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.2.6. SWOT Analysis
    
    10.7.2.7. Geographic Footprint
    
    10.7.3. Roche Holding AG
    
    10.7.3.1. Company Details
    
    10.7.3.2. Business Overview
    
    10.7.3.3. Product Portfolio
    
    10.7.3.4. Financial Insights
    
    10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.3.6. SWOT Analysis
    
    10.7.3.7. Geographic Footprint
    
    10.7.4. AstraZeneca
    
    10.7.4.1. Company Details
    
    10.7.4.2. Business Overview
    
    10.7.4.3. Product Portfolio
    
    10.7.4.4. Financial Insights
    
    10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.4.6. SWOT Analysis
    
    10.7.4.7. Geographic Footprint
    
    10.7.5. Novartis AG
    
    10.7.5.1. Company Details
    
    10.7.5.2. Business Overview
    
    10.7.5.3. Product Portfolio
    
    10.7.5.4. Financial Insights
    
    10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.5.6. SWOT Analysis
    
    10.7.5.7. Geographic Footprint
    
    10.7.6. Pfizer Inc.
    
    10.7.6.1. Company Details
    
    10.7.6.2. Business Overview
    
    10.7.6.3. Product Portfolio
    
    10.7.6.4. Financial Insights
    
    10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.6.6. SWOT Analysis
    
    10.7.6.7. Geographic Footprint
    
    10.7.7. Amgen Inc.
    
    10.7.7.1. Company Details
    
    10.7.7.2. Business Overview
    
    10.7.7.3. Product Portfolio
    
    10.7.7.4. Financial Insights
    
    10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.7.6. SWOT Analysis
    
    10.7.7.7. Geographic Footprint
    
    10.7.8. Sanofi S.A.
    
    10.7.8.1. Company Details
    
    10.7.8.2. Business Overview
    
    10.7.8.3. Product Portfolio
    
    10.7.8.4. Financial Insights
    
    10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.8.6. SWOT Analysis
    
    10.7.8.7. Geographic Footprint
    
    10.7.9. Gilead Sciences (Kite Pharma)
    
    10.7.9.1. Company Details
    
    10.7.9.2. Business Overview
    
    10.7.9.3. Product Portfolio
    
    10.7.9.4. Financial Insights
    
    10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.9.6. SWOT Analysis
    
    10.7.9.7. Geographic Footprint
    
    10.7.10. Eli Lilly and Company
    
    10.7.10.1. Company Details
    
    10.7.10.2. Business Overview
    
    10.7.10.3. Product Portfolio
    
    10.7.10.4. Financial Insights
    
    10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.10.6. SWOT Analysis
    
    10.7.10.7. Geographic Footprint
    
    10.7.11. Takeda Pharmaceutical Company
    
    10.7.11.1. Company Details
    
    10.7.11.2. Business Overview
    
    10.7.11.3. Product Portfolio
    
    10.7.11.4. Financial Insights
    
    10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.11.6. SWOT Analysis
    
    10.7.11.7. Geographic Footprint
    
    10.7.12. GlaxoSmithKline (GSK)
    
    10.7.12.1. Company Details
    
    10.7.12.2. Business Overview
    
    10.7.12.3. Product Portfolio
    
    10.7.12.4. Financial Insights
    
    10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.12.6. SWOT Analysis
    
    10.7.12.7. Geographic Footprint
    
    10.7.13. Incyte Corporation
    
    10.7.13.1. Company Details
    
    10.7.13.2. Business Overview
    
    10.7.13.3. Product Portfolio
    
    10.7.13.4. Financial Insights
    
    10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.13.6. SWOT Analysis
    
    10.7.13.7. Geographic Footprint
    
    10.7.14. Johnson & Johnson
    
    10.7.14.1. Company Details
    
    10.7.14.2. Business Overview
    
    10.7.14.3. Product Portfolio
    
    10.7.14.4. Financial Insights
    
    10.7.14.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.14.6. SWOT Analysis
    
    10.7.14.7. Geographic Footprint
    
    10.7.15. Bayer AG
    
    10.7.15.1. Company Details
    
    10.7.15.2. Business Overview
    
    10.7.15.3. Product Portfolio
    
    10.7.15.4. Financial Insights
    
    10.7.15.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.15.6. SWOT Analysis
    
    10.7.15.7. Geographic Footprint
    
    10.7.16. Genmab A/S
    
    10.7.16.1. Company Details
    
    10.7.16.2. Business Overview
    
    10.7.16.3. Product Portfolio
    
    10.7.16.4. Financial Insights
    
    10.7.16.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.16.6. SWOT Analysis
    
    10.7.16.7. Geographic Footprint
    
    10.7.17. Regeneron Pharmaceuticals
    
    10.7.17.1. Company Details
    
    10.7.17.2. Business Overview
    
    10.7.17.3. Product Portfolio
    
    10.7.17.4. Financial Insights
    
    10.7.17.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.17.6. SWOT Analysis
    
    10.7.17.7. Geographic Footprint
    
    10.7.18. BeiGene Ltd.
    
    10.7.18.1. Company Details
    
    10.7.18.2. Business Overview
    
    10.7.18.3. Product Portfolio
    
    10.7.18.4. Financial Insights
    
    10.7.18.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.18.6. SWOT Analysis
    
    10.7.18.7. Geographic Footprint
- 11. Methodology and Data Source
  - 11.1. Methodology/Research Approach
  - 11.2. Market Size Estimation
  - 11.3. Market Breakdown and Data Triangulation
  - 11.4. Data Source
  - 11.5. Secondary Sources
  - 11.6. Primary Sources
  - 11.7. Appendix
  - 11.8. Disclaimer
List of Tables
- Table 1. Global Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 2. Global Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 3. Global Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 4. Global Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 5. Global Immuno-Oncology Market Value (US$ Mn), By Region, 2020-2034
- Table 6. North America Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 7. North America Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 8. North America Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 9. North America Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 10. North America Immuno-Oncology Market Value (US$ Mn), By Country, 2020-2034
- Table 11. The US Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 12. The US Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 13. The US Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 14. The US Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 15. Canada Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 16. Canada Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 17. Canada Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 18. Canada Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 19. Europe Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 20. Europe Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 21. Europe Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 22. Europe Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 23. Europe Immuno-Oncology Market Value (US$ Mn), By Country, 2020-2034
- Table 24. Germany Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 25. Germany Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 26. Germany Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 27. Germany Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 28. The UK Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 29. The UK Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 30. The UK Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 31. The UK Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 32. France Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 33. France Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 34. France Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 35. France Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 36. Spain Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 37. Spain Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 38. Spain Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 39. Spain Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 40. Italy Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 41. Italy Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 42. Italy Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 43. Italy Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 44. Russia Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 45. Russia Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 46. Russia Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 47. Russia Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 48. Netherland Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 49. Netherland Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 50. Netherland Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 51. Netherland Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 52. Rest of Europe Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 53. Rest of Europe Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 54. Rest of Europe Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 55. Rest of Europe Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 56. Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 57. Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 58. Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 59. Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 60. Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Country, 2020-2034
- Table 61. China Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 62. China Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 63. China Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 64. China Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 65. India Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 66. India Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 67. India Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 68. India Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 69. Japan Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 70. Japan Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 71. Japan Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 72. Japan Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 73. South Korea Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 74. South Korea Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 75. South Korea Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 76. South Korea Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 77. Australia Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 78. Australia Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 79. Australia Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 80. Australia Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 81. New Zealand Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 82. New Zealand Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 83. New Zealand Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 84. New Zealand Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 85. Singapore Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 86. Singapore Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 87. Singapore Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 88. Singapore Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 89. Thailand Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 90. Thailand Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 91. Thailand Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 92. Thailand Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 93. Vietnam Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 94. Vietnam Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 95. Vietnam Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 96. Vietnam Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 97. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 98. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 99. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 100. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 101. Latin America Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 102. Latin America Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 103. Latin America Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 104. Latin America Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 105. Latin America Immuno-Oncology Market Value (US$ Mn), By Country, 2020-2034
- Table 106. Brazil Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 107. Brazil Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 108. Brazil Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 109. Brazil Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 110. Mexico Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 111. Mexico Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 112. Mexico Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 113. Mexico Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 114. Rest of Latin America Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 115. Rest of Latin America Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 116. Rest of Latin America Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 117. Rest of Latin America Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 118. Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 119. Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 120. Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 121. Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 122. Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Country, 2020-2034
- Table 123. South Africa Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 124. South Africa Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 125. South Africa Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 126. South Africa Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 127. Saudi Arabia Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 128. Saudi Arabia Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 129. Saudi Arabia Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 130. Saudi Arabia Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 131. UAE Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 132. UAE Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 133. UAE Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 134. UAE Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
- Table 135. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Therapy, 2020-2034
- Table 136. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Indication, 2020-2034
- Table 137. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Stage / Line of Therapy, 2020-2034
- Table 138. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Mn), By Distribution Channel, 2020-2034
List of Figures
- Figure 1. Global Immuno-Oncology Market Snapshot: Market Value (US$ Mn), 2020-2034
- Figure 2. Opportunity Map
- Figure 3. Opportunity Orbit
- Figure 4. Regional Market Share and BPS Analysis in Immuno-Oncology Market
- Figure 5. Global Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 6. Global Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 7. Global Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 8. Global Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 9. Global Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 10. Global Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 11. Global Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 12. Global Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 13. Global Immuno-Oncology Market Analysis, By Region, 2020, 2024 and 2034
- Figure 14. Global Immuno-Oncology Market Attractiveness Analysis, By Region
- Figure 15. North America Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 16. North America Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 17. North America Immuno-Oncology Market (US$ Mn), by Immune Checkpoint Inhibitors, 2020-2034
- Figure 18. North America Immuno-Oncology Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
- Figure 19. North America Immuno-Oncology Market (US$ Mn), by Cell & Gene Therapies, 2020-2034
- Figure 20. North America Immuno-Oncology Market (US$ Mn), by Cancer Vaccines, 2020-2034
- Figure 21. North America Immuno-Oncology Market (US$ Mn), by Oncolytic Virus Therapy, 2020-2034
- Figure 22. North America Immuno-Oncology Market (US$ Mn), by Combination Therapies, 2020-2034
- Figure 23. North America Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 24. North America Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 25. North America Immuno-Oncology Market (US$ Mn), by Solid Tumours, 2020-2034
- Figure 26. North America Immuno-Oncology Market (US$ Mn), by Hematologic Malignancies, 2020-2034
- Figure 27. North America Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 28. North America Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 29. North America Immuno-Oncology Market (US$ Mn), by First-line (frontline), 2020-2034
- Figure 30. North America Immuno-Oncology Market (US$ Mn), by Second-line, 2020-2034
- Figure 31. North America Immuno-Oncology Market (US$ Mn), by Third-line / later lines, 2020-2034
- Figure 32. North America Immuno-Oncology Market (US$ Mn), by Adjuvant (post-surgery), 2020-2034
- Figure 33. North America Immuno-Oncology Market (US$ Mn), by Neoadjuvant (pre-surgery), 2020-2034
- Figure 34. North America Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 35. North America Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 36. North America Immuno-Oncology Market (US$ Mn), by Hospital pharmacies, 2020-2034
- Figure 37. North America Immuno-Oncology Market (US$ Mn), by Retail pharmacies, 2020-2034
- Figure 38. North America Immuno-Oncology Market (US$ Mn), by Online pharmacies, 2020-2034
- Figure 39. North America Immuno-Oncology Market Analysis, By Country, 2020, 2024 and 2034
- Figure 40. North America Immuno-Oncology Market Attractiveness Analysis, By Country
- Figure 41. Europe Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 42. Europe Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 43. Europe Immuno-Oncology Market (US$ Mn), by Immune Checkpoint Inhibitors, 2020-2034
- Figure 44. Europe Immuno-Oncology Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
- Figure 45. Europe Immuno-Oncology Market (US$ Mn), by Cell & Gene Therapies, 2020-2034
- Figure 46. Europe Immuno-Oncology Market (US$ Mn), by Cancer Vaccines, 2020-2034
- Figure 47. Europe Immuno-Oncology Market (US$ Mn), by Oncolytic Virus Therapy, 2020-2034
- Figure 48. Europe Immuno-Oncology Market (US$ Mn), by Combination Therapies, 2020-2034
- Figure 49. Europe Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 50. Europe Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 51. Europe Immuno-Oncology Market (US$ Mn), by Solid Tumours, 2020-2034
- Figure 52. Europe Immuno-Oncology Market (US$ Mn), by Hematologic Malignancies, 2020-2034
- Figure 53. Europe Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 54. Europe Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 55. Europe Immuno-Oncology Market (US$ Mn), by First-line (frontline), 2020-2034
- Figure 56. Europe Immuno-Oncology Market (US$ Mn), by Second-line, 2020-2034
- Figure 57. Europe Immuno-Oncology Market (US$ Mn), by Third-line / later lines, 2020-2034
- Figure 58. Europe Immuno-Oncology Market (US$ Mn), by Adjuvant (post-surgery), 2020-2034
- Figure 59. Europe Immuno-Oncology Market (US$ Mn), by Neoadjuvant (pre-surgery), 2020-2034
- Figure 60. Europe Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 61. Europe Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 62. Europe Immuno-Oncology Market (US$ Mn), by Hospital pharmacies, 2020-2034
- Figure 63. Europe Immuno-Oncology Market (US$ Mn), by Retail pharmacies, 2020-2034
- Figure 64. Europe Immuno-Oncology Market (US$ Mn), by Online pharmacies, 2020-2034
- Figure 65. Europe Immuno-Oncology Market Analysis, By Country, 2020, 2024 and 2034
- Figure 66. Europe Immuno-Oncology Market Attractiveness Analysis, By Country
- Figure 67. Asia Pacific Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 68. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 69. Asia Pacific Immuno-Oncology Market (US$ Mn), by Immune Checkpoint Inhibitors, 2020-2034
- Figure 70. Asia Pacific Immuno-Oncology Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
- Figure 71. Asia Pacific Immuno-Oncology Market (US$ Mn), by Cell & Gene Therapies, 2020-2034
- Figure 72. Asia Pacific Immuno-Oncology Market (US$ Mn), by Cancer Vaccines, 2020-2034
- Figure 73. Asia Pacific Immuno-Oncology Market (US$ Mn), by Oncolytic Virus Therapy, 2020-2034
- Figure 74. Asia Pacific Immuno-Oncology Market (US$ Mn), by Combination Therapies, 2020-2034
- Figure 75. Asia Pacific Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 76. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 77. Asia Pacific Immuno-Oncology Market (US$ Mn), by Solid Tumours, 2020-2034
- Figure 78. Asia Pacific Immuno-Oncology Market (US$ Mn), by Hematologic Malignancies, 2020-2034
- Figure 79. Asia Pacific Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 80. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 81. Asia Pacific Immuno-Oncology Market (US$ Mn), by First-line (frontline), 2020-2034
- Figure 82. Asia Pacific Immuno-Oncology Market (US$ Mn), by Second-line, 2020-2034
- Figure 83. Asia Pacific Immuno-Oncology Market (US$ Mn), by Third-line / later lines, 2020-2034
- Figure 84. Asia Pacific Immuno-Oncology Market (US$ Mn), by Adjuvant (post-surgery), 2020-2034
- Figure 85. Asia Pacific Immuno-Oncology Market (US$ Mn), by Neoadjuvant (pre-surgery), 2020-2034
- Figure 86. Asia Pacific Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 87. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 88. Asia Pacific Immuno-Oncology Market (US$ Mn), by Hospital pharmacies, 2020-2034
- Figure 89. Asia Pacific Immuno-Oncology Market (US$ Mn), by Retail pharmacies, 2020-2034
- Figure 90. Asia Pacific Immuno-Oncology Market (US$ Mn), by Online pharmacies, 2020-2034
- Figure 91. Asia Pacific Immuno-Oncology Market Analysis, By Country, 2020, 2024 and 2034
- Figure 92. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Country
- Figure 93. Latin America Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 94. Latin America Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 95. Latin America Immuno-Oncology Market (US$ Mn), by Immune Checkpoint Inhibitors, 2020-2034
- Figure 96. Latin America Immuno-Oncology Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
- Figure 97. Latin America Immuno-Oncology Market (US$ Mn), by Cell & Gene Therapies, 2020-2034
- Figure 98. Latin America Immuno-Oncology Market (US$ Mn), by Cancer Vaccines, 2020-2034
- Figure 99. Latin America Immuno-Oncology Market (US$ Mn), by Oncolytic Virus Therapy, 2020-2034
- Figure 100. Latin America Immuno-Oncology Market (US$ Mn), by Combination Therapies, 2020-2034
- Figure 101. Latin America Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 102. Latin America Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 103. Latin America Immuno-Oncology Market (US$ Mn), by Solid Tumours, 2020-2034
- Figure 104. Latin America Immuno-Oncology Market (US$ Mn), by Hematologic Malignancies, 2020-2034
- Figure 105. Latin America Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 106. Latin America Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 107. Latin America Immuno-Oncology Market (US$ Mn), by First-line (frontline), 2020-2034
- Figure 108. Latin America Immuno-Oncology Market (US$ Mn), by Second-line, 2020-2034
- Figure 109. Latin America Immuno-Oncology Market (US$ Mn), by Third-line / later lines, 2020-2034
- Figure 110. Latin America Immuno-Oncology Market (US$ Mn), by Adjuvant (post-surgery), 2020-2034
- Figure 111. Latin America Immuno-Oncology Market (US$ Mn), by Neoadjuvant (pre-surgery), 2020-2034
- Figure 112. Latin America Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 113. Latin America Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 114. Latin America Immuno-Oncology Market (US$ Mn), by Hospital pharmacies, 2020-2034
- Figure 115. Latin America Immuno-Oncology Market (US$ Mn), by Retail pharmacies, 2020-2034
- Figure 116. Latin America Immuno-Oncology Market (US$ Mn), by Online pharmacies, 2020-2034
- Figure 117. Latin America Immuno-Oncology Market Analysis, By Country, 2020, 2024 and 2034
- Figure 118. Latin America Immuno-Oncology Market Attractiveness Analysis, By Country
- Figure 119. Middle East & Africa Immuno-Oncology Market Analysis, By Therapy, 2020, 2024 and 2034
- Figure 120. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Therapy
- Figure 121. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Immune Checkpoint Inhibitors, 2020-2034
- Figure 122. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
- Figure 123. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Cell & Gene Therapies, 2020-2034
- Figure 124. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Cancer Vaccines, 2020-2034
- Figure 125. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Oncolytic Virus Therapy, 2020-2034
- Figure 126. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Combination Therapies, 2020-2034
- Figure 127. Middle East & Africa Immuno-Oncology Market Analysis, By Indication, 2020, 2024 and 2034
- Figure 128. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Indication
- Figure 129. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Solid Tumours, 2020-2034
- Figure 130. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Hematologic Malignancies, 2020-2034
- Figure 131. Middle East & Africa Immuno-Oncology Market Analysis, By Stage / Line of Therapy, 2020, 2024 and 2034
- Figure 132. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Stage / Line of Therapy
- Figure 133. Middle East & Africa Immuno-Oncology Market (US$ Mn), by First-line (frontline), 2020-2034
- Figure 134. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Second-line, 2020-2034
- Figure 135. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Third-line / later lines, 2020-2034
- Figure 136. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Adjuvant (post-surgery), 2020-2034
- Figure 137. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Neoadjuvant (pre-surgery), 2020-2034
- Figure 138. Middle East & Africa Immuno-Oncology Market Analysis, By Distribution Channel, 2020, 2024 and 2034
- Figure 139. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Distribution Channel
- Figure 140. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Hospital pharmacies, 2020-2034
- Figure 141. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Retail pharmacies, 2020-2034
- Figure 142. Middle East & Africa Immuno-Oncology Market (US$ Mn), by Online pharmacies, 2020-2034
- Figure 143. Middle East & Africa Immuno-Oncology Market Analysis, By Country, 2020, 2024 and 2034
- Figure 144. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Country
- Merck & Co.
- Bristol-Myers Squibb (BMS)
- Roche Holding AG
- AstraZeneca
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Sanofi S.A.
- Gilead Sciences (Kite Pharma)
- Eli Lilly and Company
- Takeda Pharmaceutical Company
- GlaxoSmithKline (GSK)
- Incyte Corporation
- Johnson & Johnson
- Bayer AG
- Genmab A/S
- Regeneron Pharmaceuticals
- BeiGene Ltd.
- Other key players